Peptide Synthesis companies

Key Peptide Synthesis Market Players:

Here is a list of key players operating in the global market:

• Bachem Holding AG (Switzerland)
  • Company Overview
  • Business Strategy
  • Key Product Offerings
  • Financial Performance
  • Key Performance Indicators
  • Risk Analysis
  • Recent Development
  • Regional Presence
  • SWOT Analysis
• PolyPeptide Group (Sweden)
• CordenPharma International (Germany)
• Lonza Group AG (Switzerland)
• AmbioPharm Inc. (U.S.)
• AnaSpec Inc. (U.S.)
• CSBio Company Inc. (U.S.)
• GenScript Biotech Corporation (China)
• Pepscan Therapeutics BV (Netherlands)
• Senn Chemicals AG (Switzerland)
• Creative Peptides (U.S.)
• AAPPTec LLC (U.S.)
• Kinpep Laboratories (India)
• Peptide Institute Inc. (Japan)
• Mimotopes Pty Ltd (Australia)
• Peptron Inc. (South Korea)
• KareBay Biochem Inc. (U.S.)
• JPT Peptide Technologies GmbH (Germany)
• XLabs Peptide Synthesis (Malaysia)
• Thermo Fisher Scientific Inc. (U.S.)

The international peptide synthesis market is extremely competitive and highly dominated by established organizations in the U.S. and Europe, with emerging contributions from the Asia-Pacific. Companies such as Bachem, PolyPeptide, and Lonza leverage scale, GMP compliance, and automation to secure leading market shares. U.S. firms, such as AmbioPharm and Thermo Fisher, focus on expanding custom synthesis services, while players in Asia, including GenScript, Peptide Institute, and Peptron, drive innovation through cost-effective manufacturing and advanced technologies. Besides, in January 2024, WuXi AppTec effectively notified the commissioning of its very own two newest peptide manufacturing facilities, at the Changzhou facility and another at the newest Taixing site in China. This particular expansion has surged the organization’s solid-phase peptide synthesis overall reactor volume to 32,000 liters, thereby significantly addressing the increasing international need for peptide therapeutics.

Corporate Landscape of the Peptide Synthesis Market:

• Bachem Holding AG is widely recognized as a global leader in peptide synthesis, offering GMP-grade APIs and custom synthesis services. With more than 50 years of expertise, it dominates the market alongside Thermo Fisher and Merck, leveraging automation and scale to serve pharma and biotech worldwide.
• PolyPeptide Group is one of the major CDMOs, specializing in peptide-based APIs, with facilities across Europe, the U.S., and India. In 2025, it announced the doubling of solid-phase peptide synthesis (SPPS) capacity at its Malmö site, reinforcing its position as a high-volume supplier to global pharma.
• CordenPharma International significantly offers integrated peptide API manufacturing from early-stage development to commercial supply. The company has invested over €1 billion in peptide expansion, including new facilities in Switzerland and Germany, positioning itself as a leading European supplier of injectable and oral peptide therapeutics.
• Lonza Group AG is a diversified CDMO with strong peptide synthesis capabilities, particularly at its Visp site in Switzerland. It has invested CHF 24 million to expand peptide manufacturing, aligning with its broader biologics and advanced therapeutics portfolio.
• AmbioPharm Inc. is a full-service CDMO specializing in custom peptide APIs, with headquarters in South Carolina and additional facilities in Shanghai. It partners with pharma and biotech firms to accelerate late-stage peptide development, leveraging scalable GMP manufacturing and green chemistry approaches.